Form 4: Arbutus Biopharma CFO David Hastings Reports Stock and Option Awards

David Hastings, CFO of Arbutus Biopharma, reports the acquisition of restricted stock units and stock options.

Summary

• David Hastings, the Chief Financial Officer of Arbutus Biopharma, filed a Form 4 on February 19, 2025.
• The report details the grant of 90,100 restricted stock units (RSUs) and an option to purchase 365,800 common shares on February 14, 2025.
• The RSUs vest in three equal annual installments starting one year from the grant date.
• The stock options vest over a four-year period, with 1/48th of the shares vesting monthly from one month after the grant date.
• The exercise price for the stock options is $3.29.
• Following these transactions, Hastings beneficially owns 249,824 common shares and options for 365,800 shares.
• Common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction on each vesting date.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options encourage long-term commitment from the CFO.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a continued role for David Hastings as CFO of Arbutus Biopharma.

Industry Context

Stock and option awards are a common practice in the biopharmaceutical industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules are typical to ensure long-term commitment, often spanning three to four years.
• The size of the grant would be benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock and option awards positively as they align management's interests with the company's long-term success.
• Employees may see the awards as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Arbutus Biopharma, ABUS, David Hastings, CFO, restricted stock units, stock options, beneficial ownership, vesting